These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 32611383)

  • 21. Comparison of transarterial chemoembolization with radiofrequency ablation for unresectable Barcelona Clinic Liver Cancer stage 0/A hepatocellular carcinoma: a propensity score matching.
    Chen RX; Gan YH; Ge NL; Chen Y; Ma H; Wang Y; Zhang BH; Wang YH; Ye SL; Luo JF; Ren ZG
    J Gastroenterol Hepatol; 2016 Feb; 31(2):442-9. PubMed ID: 26259976
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hepatic decompensation is the major driver of death in HCV-infected cirrhotic patients with successfully treated early hepatocellular carcinoma.
    Cabibbo G; Petta S; Barbara M; Attardo S; Bucci L; Farinati F; Giannini EG; Negrini G; Ciccarese F; Rapaccini GL; Di Marco M; Caturelli E; Zoli M; Borzio F; Sacco R; Virdone R; Marra F; Mega A; Morisco F; Benvegnù L; Gasbarrini A; Svegliati-Baroni G; Foschi FG; Olivani A; Masotto A; Nardone G; Colecchia A; Persico M; Craxì A; Trevisani F; Cammà C;
    J Hepatol; 2017 Jul; 67(1):65-71. PubMed ID: 28192185
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nomogram for preoperative estimation of long-term survival of patients who underwent curative resection with hepatocellular carcinoma beyond Barcelona clinic liver cancer stage A1.
    Ruan DY; Lin ZX; Wang TT; Zhao H; Wu DH; Chen J; Dong M; Lin Q; Wu XY; Li Y
    Oncotarget; 2016 Sep; 7(38):61378-61389. PubMed ID: 27542216
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Improved clinical outcome using transarterial chemoembolization combined with radiofrequency ablation for patients in Barcelona clinic liver cancer stage A or B hepatocellular carcinoma regardless of tumor size: results of a single-center retrospective case control study.
    Ren Y; Cao Y; Ma H; Kan X; Zhou C; Liu J; Shi Q; Feng G; Xiong B; Zheng C
    BMC Cancer; 2019 Oct; 19(1):983. PubMed ID: 31640620
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic factors for survival after transarterial chemoembolization combined with microwave ablation for hepatocellular carcinoma.
    Ni JY; Sun HL; Chen YT; Luo JH; Chen D; Jiang XY; Xu LF
    World J Gastroenterol; 2014 Dec; 20(46):17483-90. PubMed ID: 25516662
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Recurrent hepatocellular carcinoma: a Western strategy that emphasizes the impact of pathologic profile of the first resection.
    Meniconi RL; Komatsu S; Perdigao F; Boëlle PY; Soubrane O; Scatton O
    Surgery; 2015 Mar; 157(3):454-62. PubMed ID: 25633732
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Post-transplant infection improves outcome of hepatocellular carcinoma patients after orthotopic liver transplantation.
    Chao JS; Zhao SL; Ou-Yang SW; Qian YB; Liu AQ; Tang HM; Zhong L; Peng ZH; Xu JM; Sun HC
    World J Gastroenterol; 2019 Oct; 25(37):5630-5640. PubMed ID: 31602163
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Natural killer cell activity is a risk factor for the recurrence risk after curative treatment of hepatocellular carcinoma.
    Lee HA; Goh HG; Lee YS; Jung YK; Kim JH; Yim HJ; Lee MG; An H; Jeen YT; Yeon JE; Byun KS; Seo YS
    BMC Gastroenterol; 2021 Jun; 21(1):258. PubMed ID: 34118869
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Early intrahepatic recurrence of hepatocellular carcinoma after hepatectomy treated with re-hepatectomy, ablation or chemoembolization: a prospective cohort study.
    Wang K; Liu G; Li J; Yan Z; Xia Y; Wan X; Ji Y; Lau WY; Wu M; Shen F
    Eur J Surg Oncol; 2015 Feb; 41(2):236-42. PubMed ID: 25434327
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pretreatment Inflammation-Based Markers Predict Survival Outcomes in Patients with Early Stage Hepatocellular Carcinoma After Radiofrequency Ablation.
    Chu MO; Shen CH; Chang TS; Xu HW; Yen CW; Lu SN; Hung CH
    Sci Rep; 2018 Nov; 8(1):16611. PubMed ID: 30413724
    [TBL] [Abstract][Full Text] [Related]  

  • 31. BCLC-B Subclassification and the Hong Kong Liver Cancer System in Intermediate Hepatocellular Carcinoma: Identifying Candidates for Curative Therapy.
    Longo L; Rodrigues de Freitas LB; Santos D; Grivicich I; Álvares-da-Silva MR
    Am J Clin Oncol; 2019 May; 42(5):466-471. PubMed ID: 30913090
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Microvascular invasion has limited clinical values in hepatocellular carcinoma patients at Barcelona Clinic Liver Cancer (BCLC) stages 0 or B.
    Huang C; Zhu XD; Ji Y; Ding GY; Shi GM; Shen YH; Zhou J; Fan J; Sun HC
    BMC Cancer; 2017 Jan; 17(1):58. PubMed ID: 28095820
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Benefit of Treating Hepatocellular Carcinoma Recurrence after Liver Transplantation and Analysis of Prognostic Factors for Survival in a Large Euro-American Series.
    Sapisochin G; Goldaracena N; Astete S; Laurence JM; Davidson D; Rafael E; Castells L; Sandroussi C; Bilbao I; Dopazo C; Grant DR; Lázaro JL; Caralt M; Ghanekar A; McGilvray ID; Lilly L; Cattral MS; Selzner M; Charco R; Greig PD
    Ann Surg Oncol; 2015 Jul; 22(7):2286-94. PubMed ID: 25472651
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Preoperative adjuvant transarterial chemoembolization cannot improve the long term outcome of radical therapies for hepatocellular carcinoma.
    Jianyong L; Jinjing Z; Lunan Y; Jingqiang Z; Wentao W; Yong Z; Bo L; Tianfu W; Jiaying Y
    Sci Rep; 2017 Feb; 7():41624. PubMed ID: 28155861
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Recurrent hepatocellular carcinoma has an increased risk of subsequent recurrence after curative treatment.
    Yamashiki N; Yoshida H; Tateishi R; Shiina S; Teratani T; Yoshida H; Kondo Y; Oki T; Kawabe T; Omata M
    J Gastroenterol Hepatol; 2007 Dec; 22(12):2155-60. PubMed ID: 18031374
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Survival Analysis of Advanced HCC Treated with Radioembolization: Comparing Impact of Clinical Performance Status Versus Vascular Invasion/Metastases.
    Ali R; Gabr A; Abouchaleh N; Al Asadi A; Mora RA; Kulik L; Abecassis M; Riaz A; Salem R; Lewandowski RJ
    Cardiovasc Intervent Radiol; 2018 Feb; 41(2):260-269. PubMed ID: 28879621
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Recurrence after liver resection for hepatocellular carcinoma: risk factors, treatment, and outcomes.
    Shah SA; Cleary SP; Wei AC; Yang I; Taylor BR; Hemming AW; Langer B; Grant DR; Greig PD; Gallinger S
    Surgery; 2007 Mar; 141(3):330-9. PubMed ID: 17349844
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association of Hepatitis B Virus DNA Level and Follow-up Interval With Hepatocellular Carcinoma Recurrence.
    Wang W; Tian SL; Wang H; Shao CC; Wang YZ; Li YL
    JAMA Netw Open; 2020 Apr; 3(4):e203707. PubMed ID: 32338753
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Optimal Management for Sub-Centimeter Hepatocellular Carcinoma: Curative Treatments or Follow-Up?
    Sun X; Zhang Y; Lyu N; Li X; Chen M; Zhao M
    Med Sci Monit; 2019 Jul; 25():4941-4951. PubMed ID: 31270311
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Compliance With Hepatocellular Carcinoma Surveillance Guidelines Associated With Increased Lead-Time Adjusted Survival of Patients With Compensated Viral Cirrhosis: A Multi-Center Cohort Study.
    Costentin CE; Layese R; Bourcier V; Cagnot C; Marcellin P; Guyader D; Pol S; Larrey D; De Lédinghen V; Ouzan D; Zoulim F; Roulot D; Tran A; Bronowicki JP; Zarski JP; Riachi G; Calès P; Péron JM; Alric L; Bourlière M; Mathurin P; Blanc JF; Abergel A; Serfaty L; Mallat A; Grangé JD; Attali P; Bacq Y; Wartelle C; Dao T; Thabut D; Pilette C; Silvain C; Christidis C; Nguyen-Khac E; Bernard-Chabert B; Zucman D; Di Martino V; Sutton A; Letouzé E; Imbeaud S; Zucman-Rossi J; Audureau E; Roudot-Thoraval F; Nahon P;
    Gastroenterology; 2018 Aug; 155(2):431-442.e10. PubMed ID: 29729258
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.